NCT Number: NCT06397703
Phase: PHASE3
Trial Summary: For this proposed Phase III study, unfavorable intermediate risk prostate cancer patients will be randomized to receive 6 months of Androgen Deprivation Therapy (ADT) in conjunction with stereotactic – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): NYU Langone Health
Acronym:
ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives